[go: up one dir, main page]

WO2024126771A1 - Process for preparing (z)-3-(2-(5-bromo-1h-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile - Google Patents

Process for preparing (z)-3-(2-(5-bromo-1h-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile Download PDF

Info

Publication number
WO2024126771A1
WO2024126771A1 PCT/EP2023/086010 EP2023086010W WO2024126771A1 WO 2024126771 A1 WO2024126771 A1 WO 2024126771A1 EP 2023086010 W EP2023086010 W EP 2023086010W WO 2024126771 A1 WO2024126771 A1 WO 2024126771A1
Authority
WO
WIPO (PCT)
Prior art keywords
bromo
methoxybenzonitrile
indol
indole
formyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/086010
Other languages
French (fr)
Inventor
Cécile BOUGERET
Daniel John FINNEMORE
Craig Aaron FISHER
Mahesh Jayantilal SANGANEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evexta Bio
Original Assignee
Evexta Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evexta Bio filed Critical Evexta Bio
Priority to KR1020257016032A priority Critical patent/KR20250117368A/en
Priority to CN202380078129.1A priority patent/CN120112512A/en
Priority to JP2025532018A priority patent/JP2025539491A/en
Publication of WO2024126771A1 publication Critical patent/WO2024126771A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Definitions

  • the present invention relates to the field of synthesis in organic and medicinal chemistry. More particularly, the present invention provides an improved process for preparing an anticancer agent, namely (Z)-3-(2-(5-bromo- lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile.
  • Kinesins are a superfamily of motor proteins that have ATP enzyme activity. They are involved in the normal biological activities of various cells, including mitosis, meiosis, and intracellular vesicle transport. Kinesin family member 20A (KIF20A, also known as MKlp2) is located on chromosome 5q31.2 and plays an important role in the occurrence and development of tumors. Recently, several studies have demonstrated that KIF20A may play an important role in the development and progression of many different types of cancer, such as melanoma, breast cancer, nasopharyngeal cancer, pancreatic cancer, hepatocellular carcinoma, lung cancer, and colorectal cancer.
  • WO 2014/086964 focusses on (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2- cyanovinyl)-4-methoxybenzonitrile (Example 38 of WO 2014/086964), for which it has been evaluated an efficient antitumor activity at a nanomolar efficiency on various human cancer cells, demonstrating thereby a strong interest to use this lead compound for treating a large panel of cancer including for instance acute myeloid leukemia, lymphoma, breast cancer, pancreatic cancer, lung cancer and colon cancer.
  • the inventors have developed new reactive conditions for preparing (Z)-3-(2- (5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile starting from tert-butyl 5- bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl-4-methoxybenzonitrile.
  • the inventors have shown that the replacement of sodium hydride dispersion with a more process-friendly reagent, namely sodium ethoxide solution, allows to obtain (Z)-
  • the present invention thus relates to a process for preparing (Z)-3-(2-(5-bromo- lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile comprising the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl-
  • sodium ethoxide solution is a sodium ethoxide/ethanol solution, preferably at a concentration of 21% w/w.
  • the step a) is reacted at a temperature ranging from 25 to 60 °C, preferably from 40 to 45 °C.
  • the step a) is reacted for a period from 1 to 3 hours, preferably about 2 hours.
  • the step a) is reacted at a temperature ranging from 40 to 45 °C for a period of about 2 hours.
  • sodium ethoxide solution, tert-butyl 5-bromo-3- (cyanomethyl)-lH-indole-l -carboxylate, and 3-formyl-4-methoxybenzonitrile are used at step a) in stoichiometric amount.
  • the step b) comprises the following steps: bl) adding water to mixture of step a), b2) filtering the mixture, then washing and drying the crude material, b3) optionally purifying the crude material with a MEK solution, and b4) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile .
  • (Z)-3-(2-(5-bromo- lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile (compound (6)) having the following formula: is an effective inhibitor of kinesin family member 20A (KIF20A, also known as MKlp2) , which can be used as a drug for treating, for instance, diseases or pathologies associated with dysregulation of KIF20A or its pathway, such as cancer.
  • KIF20A kinesin family member 20A
  • MKlp2 kinesin family member 20A
  • the present invention provides a simple and safe process for preparing this compound with a high yield and a high purity, starting from tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l- carboxylate and 3-formyl-4-methoxybenzonitrile, with sodium ethoxide solution.
  • the present invention relates to a process for preparing (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2- cyanovinyl)-4-methoxybenzonitrile comprising the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl- 4-methoxybenzonitrile with sodium ethoxide solution; and b) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile.
  • Sodium ethoxide also called sodium ethylate or sodium ethanolate, (CAS Number: 141-52-6) having the formula C2HsONa is a strong base, which can be dissolved in polar solvents such as methanol or ethanol.
  • sodium ethoxide is dissolved in ethanol to form sodium ethoxide/ethanol solution, preferably at a concentration of 21% w/w. It is understood that the sodium ethoxide/ethanol solution can be easily prepared by a skilled person or commercially purchased.
  • the step a) is reacted at a temperature ranging from 25 to 60 °C, from 30 to 55 °C, from 35 to 50 °C, preferably from 40 to 45 °C.
  • the step a) is reacted for a period from 1 to 3 hours, from 1.5 to 2.5 hours, preferably for a period of about 2 hours.
  • the term “about” will be understood by these skilled in the art and can vary to a certain extent according to the context in which it used. If some uses of this term are not clear for those skilled in the art depending on the context, “about” means plus or minus 30%, 20%, preferably plus or minus 10%, more preferably plus or minus 5% of the specific term.
  • the invention relates to a process for preparing (Z)-3-(2-(5-bromo- lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile comprising the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl- 4-methoxybenzonitrile with sodium ethoxide/ethanol solution at a temperature ranging from 40 to 45 °C for a period of about 2 hours; and b) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile.
  • sodium ethoxide solution, tert-butyl 5-bromo-3- (cyanomethyl)-lH-indole-l -carboxylate, and 3-formyl-4-methoxybenzonitrile at step a) are used in stoichiometric amounts.
  • each of sodium ethoxide/ethanol solution, tert-butyl 5-bromo-3- (cyanomethyl)-lH-indole-l -carboxylate and 3 -formyl-4- methoxybenzonitrile is used at 1.00- 1.05 equivalents relative to the others.
  • 1.00 equivalent of tert-butyl 5-bromo-3- (cyanomethyl)-lH-indole-l -carboxylate, 1.00 equivalent of sodium ethoxide/ethanol solution, and 1.02 equivalents of 3-formyl-4-methoxybenzonitrile are used in the step a) as defined herein.
  • Step b) of the process of the invention relating to the recovering of (Z)-3-(2-(5-bromo-lH- indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile can be easily performed by a skilled person including non-exhaustive steps of quenching, filtering, washing, purifying and drying steps.
  • step b) of the process of the invention may further comprise the following steps: bl) adding water to mixture of step a), b2) filtering the mixture, then washing and drying the crude material, b3) optionally purifying the crude material with a MEK solution, and b4) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile .
  • the process of the invention comprises the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl- 4-methoxybenzonitrile with sodium ethoxide/ethanol solution; and bl) adding water to mixture of step a), b2) filtering the mixture, then washing and drying the crude material, b3) optionally purifying the crude material with a MEK solution, and b4) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile .
  • the process of the invention comprises the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl- 4-methoxybenzonitrile wit sodium ethoxide/ethanol solution, at a temperature ranging from 40 to 45 °C for a period of about 2 hours; and bl) adding water to mixture of step a), b2) filtering the mixture, then washing and drying the crude material, b3) optionally purifying the crude material with a MEK solution, and b4) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile .
  • tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l -carboxylate and 3-formyl- 4-methoxybenzonitrile can be prepared by a skilled person thanks to any known methods of synthesis including any chemical synthesis currently used in organic chemistry. These starting materials can even be commercially purchased (tert-butyl 5-bromo-3-(cyanomethyl)-lH- indole-1 -carboxylate, CAS Number: 1419874-03-5; and 3-formyl-4-methoxybenzonitrile, (CAS Number: 21962-53-8).
  • tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl-4- methoxybenzonitrile can be prepared by procedures of synthesis disclosed by WO 2014/086964.
  • tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate is prepared by a process comprising the following steps of:
  • 3-formyl-4-methoxybenzonitrile is prepared by a process comprising the following steps of:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

The present invention relates to a process for preparing (Z)-3-(2-(5-bromo-1H-indol-3-yl)-2- cyanovinyl)-4-methoxybenzonitrile comprising reacting tert-butyl 5-bromo-3-(cyanomethyl)- 1H-indole-1-carboxylate, 3-formyl-4-methoxybenzonitrile, and sodium ethoxide solution.

Description

PROCESS FOR PREPARING (Z)-3-(2-(5-BROMO-lH-INDOL-3-YL)-2-CYANOVINYL)-
4-METH0XYBENZ0NITRILE
FIELD OF THE INVENTION
The present invention relates to the field of synthesis in organic and medicinal chemistry. More particularly, the present invention provides an improved process for preparing an anticancer agent, namely (Z)-3-(2-(5-bromo- lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile.
BACKGROUND OF THE INVENTION
Kinesins are a superfamily of motor proteins that have ATP enzyme activity. They are involved in the normal biological activities of various cells, including mitosis, meiosis, and intracellular vesicle transport. Kinesin family member 20A (KIF20A, also known as MKlp2) is located on chromosome 5q31.2 and plays an important role in the occurrence and development of tumors. Recently, several studies have demonstrated that KIF20A may play an important role in the development and progression of many different types of cancer, such as melanoma, breast cancer, nasopharyngeal cancer, pancreatic cancer, hepatocellular carcinoma, lung cancer, and colorectal cancer.
In past years, a class of indole derivatives as compounds targeting KIF20A (MKlp2) has been developed such as compounds described in the international patent application WO 2014/086964.
More particularly, WO 2014/086964 focusses on (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2- cyanovinyl)-4-methoxybenzonitrile (Example 38 of WO 2014/086964), for which it has been evaluated an efficient antitumor activity at a nanomolar efficiency on various human cancer cells, demonstrating thereby a strong interest to use this lead compound for treating a large panel of cancer including for instance acute myeloid leukemia, lymphoma, breast cancer, pancreatic cancer, lung cancer and colon cancer. (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2- cyanovinyl)-4-methoxybenzonitrile is obtained by reacting tert-butyl 5-bromo-3- (cyanomethyl)-lH-indole-l -carboxylate with sodium hydride dispersion (NaH) and, then adding 3-formyl-4-methoxybenzonitrile. However, this synthesis reaction using NaH does not meet the requirements of an industrial scale and safety. Indeed, (Z)-3-(2-(5-bromo-lH-indol-3- yl)-2-cyanovinyl)-4-methoxybenzonitrile is only obtained with 30% yield, and the use of NaH involves delayed reaction onset and exotherm, evolution of hydrogen gas, and potential contamination of the final product with mineral oil.
Therefore, there is a need to develop and provide process for the synthesis of (Z)-3-(2-(5- bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile suitable for industrial scale, including economical and safety objectives.
SUMMARY OF THE INVENTION
In this context, the inventors have developed new reactive conditions for preparing (Z)-3-(2- (5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile starting from tert-butyl 5- bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl-4-methoxybenzonitrile. Unexpectedly, the inventors have shown that the replacement of sodium hydride dispersion with a more process-friendly reagent, namely sodium ethoxide solution, allows to obtain (Z)-
3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile with an improved yield of 74% and a high LCMS purity of 99.1%.
Accordingly, the present invention thus relates to a process for preparing (Z)-3-(2-(5-bromo- lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile comprising the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl-
4-methoxybenzonitrile with sodium ethoxide solution; and b) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile.
Particularly, sodium ethoxide solution is a sodium ethoxide/ethanol solution, preferably at a concentration of 21% w/w.
In a particular embodiment, the step a) is reacted at a temperature ranging from 25 to 60 °C, preferably from 40 to 45 °C.
In a further particular embodiment, the step a) is reacted for a period from 1 to 3 hours, preferably about 2 hours.
In a preferred embodiment, the step a) is reacted at a temperature ranging from 40 to 45 °C for a period of about 2 hours. In a further preferred embodiment, sodium ethoxide solution, tert-butyl 5-bromo-3- (cyanomethyl)-lH-indole-l -carboxylate, and 3-formyl-4-methoxybenzonitrile are used at step a) in stoichiometric amount.
In a particular embodiment, the step b) comprises the following steps: bl) adding water to mixture of step a), b2) filtering the mixture, then washing and drying the crude material, b3) optionally purifying the crude material with a MEK solution, and b4) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile .
DETAILED DESCRIPTION OF THE INVENTION
(Z)-3-(2-(5-bromo- lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile (compound (6)) having the following formula:
Figure imgf000004_0001
is an effective inhibitor of kinesin family member 20A (KIF20A, also known as MKlp2) , which can be used as a drug for treating, for instance, diseases or pathologies associated with dysregulation of KIF20A or its pathway, such as cancer.
The present invention provides a simple and safe process for preparing this compound with a high yield and a high purity, starting from tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l- carboxylate and 3-formyl-4-methoxybenzonitrile, with sodium ethoxide solution.
The present invention relates to a process for preparing (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2- cyanovinyl)-4-methoxybenzonitrile comprising the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl- 4-methoxybenzonitrile with sodium ethoxide solution; and b) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile. Sodium ethoxide, also called sodium ethylate or sodium ethanolate, (CAS Number: 141-52-6) having the formula C2HsONa is a strong base, which can be dissolved in polar solvents such as methanol or ethanol. In a preferred embodiment sodium ethoxide is dissolved in ethanol to form sodium ethoxide/ethanol solution, preferably at a concentration of 21% w/w. It is understood that the sodium ethoxide/ethanol solution can be easily prepared by a skilled person or commercially purchased.
In a particular embodiment, the step a) is reacted at a temperature ranging from 25 to 60 °C, from 30 to 55 °C, from 35 to 50 °C, preferably from 40 to 45 °C.
In a further particular embodiment, the step a) is reacted for a period from 1 to 3 hours, from 1.5 to 2.5 hours, preferably for a period of about 2 hours.
As used herein, the term “about” will be understood by these skilled in the art and can vary to a certain extent according to the context in which it used. If some uses of this term are not clear for those skilled in the art depending on the context, “about” means plus or minus 30%, 20%, preferably plus or minus 10%, more preferably plus or minus 5% of the specific term.
In a preferred embodiment, the invention relates to a process for preparing (Z)-3-(2-(5-bromo- lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile comprising the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl- 4-methoxybenzonitrile with sodium ethoxide/ethanol solution at a temperature ranging from 40 to 45 °C for a period of about 2 hours; and b) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile.
In a further particular embodiment, sodium ethoxide solution, tert-butyl 5-bromo-3- (cyanomethyl)-lH-indole-l -carboxylate, and 3-formyl-4-methoxybenzonitrile at step a) are used in stoichiometric amounts.
It is well understood that a skilled person in art, such as an organic chemist, knows the concept of stoichiometric amounts. For instance, it means that sodium ethoxide solution or sodium ethoxide/ethanol solution, tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate, and 3-formyl-4-methoxybenzonitrile reacts with about the same molar amount or with a molar ratio equal to about 1. For instance, each of sodium ethoxide/ethanol solution, tert-butyl 5-bromo-3- (cyanomethyl)-lH-indole-l -carboxylate and 3 -formyl-4- methoxybenzonitrile is used at 1.00- 1.05 equivalents relative to the others. Preferably, 1.00 equivalent of tert-butyl 5-bromo-3- (cyanomethyl)-lH-indole-l -carboxylate, 1.00 equivalent of sodium ethoxide/ethanol solution, and 1.02 equivalents of 3-formyl-4-methoxybenzonitrile are used in the step a) as defined herein.
Step b) of the process of the invention relating to the recovering of (Z)-3-(2-(5-bromo-lH- indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile can be easily performed by a skilled person including non-exhaustive steps of quenching, filtering, washing, purifying and drying steps.
For instance, step b) of the process of the invention may further comprise the following steps: bl) adding water to mixture of step a), b2) filtering the mixture, then washing and drying the crude material, b3) optionally purifying the crude material with a MEK solution, and b4) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile .
In a preferred embodiment, the process of the invention comprises the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl- 4-methoxybenzonitrile with sodium ethoxide/ethanol solution; and bl) adding water to mixture of step a), b2) filtering the mixture, then washing and drying the crude material, b3) optionally purifying the crude material with a MEK solution, and b4) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile .
In a more preferred embodiment, the process of the invention comprises the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl- 4-methoxybenzonitrile wit sodium ethoxide/ethanol solution, at a temperature ranging from 40 to 45 °C for a period of about 2 hours; and bl) adding water to mixture of step a), b2) filtering the mixture, then washing and drying the crude material, b3) optionally purifying the crude material with a MEK solution, and b4) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile .
Starting materials tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l -carboxylate and 3-formyl- 4-methoxybenzonitrile can be prepared by a skilled person thanks to any known methods of synthesis including any chemical synthesis currently used in organic chemistry. These starting materials can even be commercially purchased (tert-butyl 5-bromo-3-(cyanomethyl)-lH- indole-1 -carboxylate, CAS Number: 1419874-03-5; and 3-formyl-4-methoxybenzonitrile, (CAS Number: 21962-53-8).
For instance, tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl-4- methoxybenzonitrile can be prepared by procedures of synthesis disclosed by WO 2014/086964.
In a particular embodiment, tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate is prepared by a process comprising the following steps of:
- reacting 5-bromo-lH-indole-3-carbaldehyde with formamide, methanol, and sodium borohydride, then adding potassium cyanide and stirring the resulting mixture at a temperature ranging from 40 to 45 °C to yield 2-(5-bromo-lH-indol-3-yl)acetonitrile; and
- reacting 2-(5 -bromo- IH-indol- 3 -yl) acetonitrile with di-tert-butyl-dicarbonate and 4- dimethylaminopyridine with acetonitrile at room temperature; and
- recovering tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate.
In a particular embodiment, 3-formyl-4-methoxybenzonitrile is prepared by a process comprising the following steps of:
- reacting 4-fluoro-3-formylbenzonitrile with methanol, and sodium methoxide at room temperature to yield 3-formyl-4-methoxybenzonitrile; and
- recovering 3-formyl-4-methoxybenzonitrile.
Further aspects and advantages of the present invention will be described in the following examples, which should be regarded as illustrative and not limiting. EXAMPLES
The process for preparing preparing (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile is reproduced by Scheme 1 below.
Scheme 1:
Figure imgf000008_0001
1. Synthesis of tert-butyl 5-bromo-3-(cvanomethyl)-lH-indole-l-carboxylate (3)
1.1. Synthesis of 2-(5-bromo-lH-indol-3-yl)acetonitrile (2)
To a solution of 5-bromo-lH-indole-3-carbaldehyde (1 eq.) (1) in methanol: formamide (7:1) was added sodium borohydride at 0-10 °C. Then, the reaction mixture was stirred at room temperature for 30 minutes and potassium cyanide (2.5 eq.) was added. The mixture was stirred at 40 to 45 °C for 12 hours, then quenched with water. The crude residue was filtered, washed with EtOEfcEhO (1:1) and dried to afford 2-(5-bromo-lH-indol-3-yl)acetonitrile (2) with 57% yield.
1.2. Synthesis of tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate (3)
To a solution of di-tert-butyl-dicarbonate (1.1 eq.) and dimethylaminopyridine (0.05 eq.) in acetonitrile was added 2-(5-bromo-lH-indol-3-yl)acetonitrile (2) (1 eq.) at room temperature. Then, the reaction mixture was stirred at room temperature for 1 hour, then quenched with water. The crude residue was filtered, washed with heptane and dried to afford tert-butyl 5- bromo-3-(cyanomethyl)-lH-indole-l-carboxylate (3) with 93% yield.
2. Synthesis of 3-formyl-4-methoxybenzonitrile (5)
To a solution of 4-fluoro-3-formylbenzonitrile (4) (1 eq.) in methanol was added 5.4 M sodium methoxide/methanol solution (1.05 eq.) at 0-10 °C. Then, the reaction mixture was stirred at room temperature for 1.5 hour, and quenched with water. The crude residue was filtered, washed with heptane and dried to afford 3-formyl-4-methoxybenzonitrile (5) with 69% yield.
3. Synthesis of (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cvanovinyl)-4-methoxybenzonitrile
(6) (process according to the invention)
To a solution of tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l -carboxylate (3) (leq.) and formyl-4-methoxybenzonitrile (5) (1.02 eq.) in Ethanol was added sodium ethoxide/ethanol solution (1.00 eq.) at room temperature. Then, the reaction mixture was stirred at 40 to 45 °C for 2 hours, and quenched with water. The crude residue was filtered, washed with Ethanol, and dried. Material was added to Methyl Ethyl Ketone solution (MEK) and temperature was adjusted to 70-75 °C. Then, MEK solution was clarified by filtration. Filtrates were concentrated and the solid was then dried to afford (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2- cyanovinyl)-4-methoxybenzonitrile with 74% yield.
APCI-MS: (M-H) = 376
NMR (300 MHz, DMSO-d6) 5 ppm: 11.99 (s, 1H), 8.22 (s, 1H), 8.08 (s, 1H), 7.91 (s, 2H), 7.70 (s, 1H), 7.60 - 7.15 (m, 3H), 3.97 (s, 3H).
LCMS purity: 99.1%
4. Synthesis of (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cvanovinyl)-4-methoxybenzonitrile
To a solution of tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate (3) (leq.) in THF was added sodium hydride (1.5 eq.) under an argon atmosphere at 0-5 °C. Then, 3-formyl- 4-methoxybenzonitrile (5) (1.2 eq.) was added in portions and the reaction mixture was stirred at room temperature for 1.5 hour. The reaction mixture was diluted with water. The resulting solid was filtered, washed successively with water, CH2Q2, DIPE and acetonitrile and dried in vacuo to afford (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile with 30% yield.

Claims

1. A process for preparing (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile comprising the steps of: a) reacting tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate and 3-formyl- 4-methoxybenzonitrile with sodium ethoxide solution; and b) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile.
2. The process according to claim 1, wherein sodium ethoxide solution is a sodium ethoxide/ethanol solution, preferably at a concentration of 21% w/w.
3. The process according to claim 1 or 2, wherein step a) is reacted at a temperature ranging from 25 to 60 °C.
4. The process according to any one of claims 1 to 3, wherein step a) is reacted at a temperature ranging from 40 to 45 °C.
5. The process according to any one of claims 1 to 4, wherein step a) is reacted for a period from 1 to 3 hours.
6. The process according to any one of claims 1 to 5, wherein step a) is reacted for a period of about 2 hours.
7. The process according to any one of claims 1 to 6, wherein step a) is reacted at a temperature ranging from 40 to 45 °C for a period of about 2 hours.
8. The process according to any one of claims 1 to 7, wherein sodium ethoxide solution, tertbutyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate, and 3-formyl-4- methoxybenzonitrile at step a) are used in stoichiometric amounts.
9. The process according to any of claims 1 to 8, wherein step b) comprise the following steps: bl) adding water to mixture of step a), b2) filtering the mixture, then washing and drying the crude material, b3) optionally purifying the crude material with a MEK solution, and b4) recovering (Z)-3-(2-(5-bromo-lH-indol-3-yl)-2-cyanovinyl)-4- methoxybenzonitrile .
10. The process according to any one of claims 1 to 9, wherein tert-butyl 5-bromo-3- (cyanomethyl)-lH-indole-l -carboxylate is prepared by a process comprising the following steps of:
- reacting 5-bromo-lH-indole-3-carbaldehyde with formamide, methanol, and sodium borohydride, then adding potassium cyanide and stirring the resulting mixture at a temperature ranging from 40 to 45 °C to yield 2-(5-bromo-lH-indol-3-yl)acetonitrile; and
- reacting 2-(5 -bromo- IH-indol- 3 -yl) acetonitrile with di-tert-butyl-dicarbonate and 4- dimethylaminopyridine with acetonitrile at room temperature; and
- recovering tert-butyl 5-bromo-3-(cyanomethyl)-lH-indole-l-carboxylate.
11. The process according to any one of claims 1 to 9, wherein 3-formyl-4-methoxybenzonitrile is prepared by a process comprising the following steps of:
- reacting 4-fluoro-3-formylbenzonitrile with methanol, and sodium methoxide at room temperature to yield 3-formyl-4-methoxybenzonitrile; and
- recovering 3-formyl-4-methoxybenzonitrile.
PCT/EP2023/086010 2022-12-16 2023-12-15 Process for preparing (z)-3-(2-(5-bromo-1h-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile Ceased WO2024126771A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020257016032A KR20250117368A (en) 2022-12-16 2023-12-15 Method for preparing (Z)-3-(2-(5-bromo-1H-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile
CN202380078129.1A CN120112512A (en) 2022-12-16 2023-12-15 Method for preparing (Z)-3-(2-(5-bromo-1H-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile
JP2025532018A JP2025539491A (en) 2022-12-16 2023-12-15 Process for preparing (Z)-3-(2-(5-bromo-1H-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22306921.2 2022-12-16
EP22306921 2022-12-16

Publications (1)

Publication Number Publication Date
WO2024126771A1 true WO2024126771A1 (en) 2024-06-20

Family

ID=84901723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/086010 Ceased WO2024126771A1 (en) 2022-12-16 2023-12-15 Process for preparing (z)-3-(2-(5-bromo-1h-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile

Country Status (4)

Country Link
JP (1) JP2025539491A (en)
KR (1) KR20250117368A (en)
CN (1) CN120112512A (en)
WO (1) WO2024126771A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014086964A1 (en) 2012-12-07 2014-06-12 Biokinesis New derivatives of indole for the treatment of cancer, viral infections and lung diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014086964A1 (en) 2012-12-07 2014-06-12 Biokinesis New derivatives of indole for the treatment of cancer, viral infections and lung diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
no. 1419874-03-5

Also Published As

Publication number Publication date
KR20250117368A (en) 2025-08-04
JP2025539491A (en) 2025-12-05
CN120112512A (en) 2025-06-06

Similar Documents

Publication Publication Date Title
WO2024126771A1 (en) Process for preparing (z)-3-(2-(5-bromo-1h-indol-3-yl)-2-cyanovinyl)-4-methoxybenzonitrile
CN109651271B (en) A kind of synthetic method of 3-tert-butyl-N-methylquinoxaline-2(1H)-one compound
JP3536480B2 (en) 4,5-Dihalogeno-6-dihalogenomethylpyrimidine and process for producing the same
JPH061776A (en) Production of substituted pyrazinecarbonitrile
JP3259191B2 (en) Synthesis of 2,2'-anhydroarabinosyl thymine derivatives
JP3059007B2 (en) Method for producing 1- (2-carboxyphenyl) indazole derivative
JP4004082B2 (en) Method for producing cyclic nitroguanidine derivatives
JPH10130244A (en) Method for producing acyclonucleoside
JPH0220638B2 (en)
JPH01143878A (en) Production of silicon azide
WO2010079813A1 (en) Method for manufacturing inosine derivative
JP3527255B2 (en) 6-N-substituted aminopicolinic acid derivatives and their production
US6593475B1 (en) Preparation of derivative of 3-sulfonamido-4-phenylaminopyridine
JPH06228103A (en) New octahydroacridine derivative and its production
AU2017258665A1 (en) Process for the preparation of herbicidal compounds
JP3495774B2 (en) Method for producing 1-hydroxyindoles
JP6868890B2 (en) Method for producing nitrogen-containing cyclic compound having a substituent on the ring
JP4491104B2 (en) Method for producing carbonyl compound
JP2784920B2 (en) 1,3-cyclohexanedione derivative
JP4055246B2 (en) 5-chloro-6- (α-fluoroalkyl) -4-pyrimidone and process for producing the same
JP2649122B2 (en) 4,5-Dihalogeno-6- (α-substituted ethyl) pyrimidine and process for producing the same
JPH01319496A (en) uracil derivative
JP2001081080A (en) Production of 4(5)-chloromethyl-2-phenyl-1,2,3-triazole derivative
CN101747268A (en) Method for synthesizing 4-substituted-3-bromo-2-quinolone
JPH035466A (en) Method for producing phenoxyethylaminopyrimidine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23832766

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202380078129.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 202517052379

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2025532018

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025532018

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 202380078129.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202517052379

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 1020257016032

Country of ref document: KR

122 Ep: pct application non-entry in european phase

Ref document number: 23832766

Country of ref document: EP

Kind code of ref document: A1